Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, and Alvin J. Siteman Cancer Center, St. Louis, MO, United States of America.
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California San Francisco, CA, United States of America.
Gynecol Oncol. 2024 Oct;189:1-8. doi: 10.1016/j.ygyno.2024.07.001. Epub 2024 Jul 5.
Tissue banking procedures have evolved to keep pace with precision medicine, technology, emerging understanding of racial disparities, and regulatory requirements. However, there is little published guidance regarding strategies to create and maintain a successful biorepository. Our objective is to describe the infrastructure and protocols used by our Gynecologic Oncology Tissue Bank.
Our Tissue Bank was founded in 1992. In August 2022, internal funding was used to modernize the Tissue Bank. We hired three full-time employees, implemented universal screening of patients treated by gynecologic oncology faculty, updated consenting protocols, and standardized communication with providers. Tumor tissue, blood derivatives, ascites, and pleural fluid were collected from eligible, consenting patients and processed. Patient-derived cell lines and organoids were generated. For quality control purposes, one formalin-fixed, paraffin-embedded (FFPE) sample per tissue site was analyzed by a board-certified pathologist. All samples were labeled and tracked in an OpenSpecimen collection protocol and clinically annotated in a secure database.
From August 2022 to October 2023, 227 patients (83% white, 15% Black, 1% Asian) were enrolled and 4249 specimens were collected. Adherent cell lines were generated from 15 patients with ovarian cancer and cell suspensions for organoid generation were collected from 46 patients with ovarian cancer. A recharge center was established to self-sustain the Tissue Bank. Samples have been shared with academic and commercial collaborators.
Our Tissue Bank has enrolled a large number of diverse patients, collected numerous specimen types, and collaborated widely. The procedures described here provide guidance for other institutions establishing similar resources.
组织库的操作流程不断发展，以适应精准医学、技术、对种族差异的新认识和监管要求。然而，关于创建和维持成功的生物库的策略，发表的指导意见很少。我们的目标是描述我们妇科肿瘤组织库使用的基础设施和方案。
我们的组织库成立于 1992 年。2022 年 8 月，内部资金用于组织库的现代化建设。我们聘请了三名全职员工，对妇科肿瘤学教师治疗的患者进行了普遍筛查，更新了同意书协议，并规范了与提供者的沟通。从符合条件、同意的患者中收集肿瘤组织、血液衍生物、腹水和胸腔积液，并进行处理。生成患者来源的细胞系和类器官。为了质量控制目的，由认证的病理学家对每个组织部位的一个福尔马林固定、石蜡包埋（FFPE）样本进行分析。所有样本均在 OpenSpecimen 采集方案中进行标记和跟踪，并在安全数据库中进行临床注释。
从 2022 年 8 月到 2023 年 10 月，227 名患者（83%为白人，15%为黑人，1%为亚洲人）入组，收集了 4249 份标本。从 15 名卵巢癌患者中生成了贴壁细胞系，从 46 名卵巢癌患者中收集了用于类器官生成的细胞悬液。建立了一个再充电中心，以维持组织库的自我可持续性。样本已与学术和商业合作者共享。
我们的组织库已招募了大量不同种族的患者，收集了多种类型的标本，并进行了广泛的合作。此处描述的程序为其他机构建立类似资源提供了指导。
